17 Aug Fluoroquinolones: risk of mitral and aortic regurgitation associated with the use of oral and injectable fluoroquinolones
Posted at 12:47h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), the companies listed below would like to inform you about the risk of mitral and aortic regurgitation that should be taken into consideration when prescribing oral fluoroquinolone antibiotics.
2020 Jun
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
10/06/2020
File Type:
pdf
Category:
Communication To Health Care Professionals